Health Care & Life Sciences » Pharmaceuticals | Astellas Pharma Inc.

Astellas Pharma Inc.

Astellas Pharma Inc. ADR
Stock Exchange Other OTC
EPS
$1.03
Market Cap
$26.05 B
Shares Outstanding
1.89 B
Public Float
-
Astellas Pharma Inc.
Stock Exchange Other OTC
EPS
$1.03
Market Cap
$26.15 B
Shares Outstanding
1.98 B
Public Float
-
Astellas Pharma Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
1.98 B
Public Float
-
Astellas Pharma Inc.
Stock Exchange Tokyo Stock Exchange
EPS
JPY115.01
Market Cap
JPY2.84 T
Shares Outstanding
1.89 B
Public Float
1.8 B

Profile

Address
2-5-1 Nihonbashi-Honcho
Tokyo Tokyo 103
Japan
Employees -
Website http://www.astellas.com
Updated 07/08/2019
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard.

Financials

View All

Yoshihiko Hatanaka
Chairman
Kenji Yasukawa
President, CEO & Representative Director